New drug combo targets genetic fatty liver disease
NCT ID NCT07527910
First seen Apr 16, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study tests a new drug, ALN-PNP, alone or with a diabetes/weight-loss drug (like tirzepatide), in adults with a genetic form of fatty liver disease (MASLD). The goal is to see if lowering a specific protein (PNPLA3) can reduce liver fat. About 204 people with a specific gene variant and high liver fat will participate. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.